Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 25 of 2519

TitleReference numberPublishedLast updated
Avelumab with axitinib for untreated advanced renal cell carcinomaTA1120
Overweight and obesity managementNG246
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)TA1118
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTA1119
VA ECMO for postcardiotomy cardiogenic shock in adultsIPG810
DMD Care UK's guideline on respiratory care: NICE reviewNR2
Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiencyTA1117
Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemiaTA1116
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathyTA1115
Digital platforms to support cardiac rehabilitation: early value assessmentHTG764
Child maltreatment: when to suspect maltreatment in under 18sCG89
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphomaTA1113
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1114
Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early managementNG255
Suspected sepsis in people aged 16 or over: recognition, assessment and early managementNG253
Suspected sepsis in under 16s: recognition, diagnosis and early managementNG254
Suspected sepsis in over 16sQS213
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Intrapartum careNG235
Low-energy contact X-ray brachytherapy for rectal cancerIPG809
Fetal monitoring in labourNG229
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108

Results per page

  1. 10
  2. 25
  3. 50
  4. All